Veraxa Biotech Details BiTAC Pipeline Progress, Targets Lead Candidate VXA-102 for IND/CTA Readiness by Early 2028
VRXA sits 24% above its 52-week low of $1.7 on elevated volume (3.8× avg).
Summary
Veraxa Biotech provided a corporate and pipeline update, detailing progress on its proprietary BiTAC platform. The company's pipeline now includes four BiTAC-based T-cell engager programs and two bispecific ADC programs, alongside two non-BiTAC assets available for partnering. This follows the company's recent de-SPAC transaction in June and a June 18th 6-K filing which announced successful in vitro proof-of-concept for its BiTAC-ADC platform. Veraxa aims to advance its lead BiTAC-TCE candidate, VXA-102, to IND/CTA readiness by early 2028, and plans to monetize non-BiTAC programs to fund its core BiTAC portfolio. The progress of VXA-102 towards IND/CTA readiness by early 2028 will be a key milestone.
At the time of this announcement, VRXA was trading at $2.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.6M. The 52-week trading range was $1.70 to $27.36. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: FinanceWire.